

Orphan drug market has potential to grow at a CAGR of 9.2 % by 2022

orphan drugs market Information, pharmacological class (Protein & Enzyme Replacement,), By Applications, By technology and by BY source - Forecast Till 2022

PUNE, MAHARASHTRA, INDIA, August 8, 2017 / EINPresswire.com/ -- Market Highlights:

<u>Global Orphan drug market</u> is expected to grow at a CAGR of " 9.2 % during the period 2016 to 2022. Orphan drugs are used Major Key Players are for the treatment of rare diseases and disorders that affects a Hoffmann- La Roche, small percentage of the population. Celgene Corporation, Alexion The orphan drug market is characterized by huge price Pharmaceuticals, Inc., margin which guarantees an excellent rate of return. Severe Novartis AG. Takeda lack of effective substitute and the inelastic nature of demand Pharmaceuticals Company lead to dominance of the supplier. Limited, Biogen Idec Limited, Eli Lilly, This coupled with government incentives for orphan drugs make it a high risk and high return market. The ,, orphan drug market favors companies with expertise and a

Market Research Future

strong research and development pipeline. Thus the strategy of most companies revolves around more for more and

nothing for less. The market is also extremely sensitive to technological disruptions and is highly volatile as only a few drugs dominate the market. Thus the market is extremely unitary with only a small number of companies. The uptake of the drug product is guicker and there is considerable first mover advantage. The limited number and the limited buying power of patients especially in developing nations are important factors constraining the market. Volatility and over dependence on a few drugs are risks faced by companies.

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/2312

Major Key Players

- Hoffmann- La Roche,
- Celgene Corporation.
- Alexion Pharmaceuticals, Inc.,
- Novartis AG.
- Takeda Pharmaceuticals Company Limited,
- Biogen Idec Limited,
- Eli Lilly,
- Bristol-Myers Squibb,
- Vertex pharmaceuticals, Inc.
- Bayer AG,
- Sanofi,
- Johnson & Johnson.

Global Orphan drug market:

The Global Orphan drug market has been evaluated as a rapidly growing market and it is expected that the market will reflect good but explosive growth in future. The global Orphan drug market is expected to grow with a CAGR of ~ 9.2 % during the forecast period.

Test the market data and market information presented through more than 60 market data tables and figures spread over 80 numbers of pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on "<u>Global Orphan drug Market Research Report - Forecast to 2022</u>".

Regional Analysis:

Depending on geographic region, Orphan drug market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America is the largest market for Orphan drugs. Europe is the second-largest market for orphan drugs. The orphan drug market is likely to be led by these developed nations in the near future with developing regions such as Asia pacific region and Middle East & Africa providing faster growth rates.

Segmentation:

Global Orphan drugs market has been segmented on the basis of pharmacological class which comprises protein replacement, enzyme replacement, gene and chromosome expression etc. On the basis of application; market is segmented into Blood-related disorders, neurology, oncology, nephrology and infectious diseases. On the basis of technology into DNA recombination, transgenic etc; and by source into Non-biological orphan drugs and Biological orphan drugs

Access Report Details @ https://www.marketresearchfuture.com/reports/orphan-drugs-market

Table of Contents

- 1 Introduction
- 1.1 Definition
- 1.2 Scope of Study
- 1.3 Research Objective
- 1.4 Assumptions & Limitations
- 1.5 Market Structure
- 2 Research Methodology

Continued.....

List of Tables

TABLE 1GLOBAL ORPHAN DRUGS MARKET, 2013-2022 (USD MILLION)TABLE 2GLOBAL ORPHAN DRUGS MARKET, BY APPLICATION, 2013-2022 (USD MILLION)TABLE 3GLOBAL ORPHAN DRUGS MARKET, BY PHARMACOLOGICAL CLASS, 2013-2022(USD MILLION)Continued.....

List of Figures FIGURE 1 RESEARCH PROCESS FIGURE 2 PORTERS FIVE FORCES MODEL FIGURE 3 GLOBAL ORPHAN DRUGS MARKET, BY APPLICATION FIGURE 4 GLOBAL ORPHAN DRUGS MARKET, BY PHARMACOLOGICAL CLASS Continued.....

Browse Related Statistical Report

<u>Global Direct Laryngoscopes Market</u>, is projected to grow at a CAGR of 4.9% during the forecasted period at USD 522 Million. Among the various region North America contributes the largest market share of 47.8% towards global direct laryngoscopes market.

https://www.marketresearchfuture.com/statistical-reports/direct-laryngoscopes-market-2143

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact Info: Name: Akash Anand Organization: Market Research Future Address: Market Research Future Office No. 524/528, Phone: +1 646 845 9312 Email: akash.anand@marketresearchfuture.com

Akash Anand Market Research Future +1-646-845-9349 (US) / +44 208 133 9349 (UK) email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2017 IPD Group, Inc. All Right Reserved.